2021 Q3 Form 10-Q Financial Statement
#000156459021056269 Filed on November 10, 2021
Income Statement
Concept | 2021 Q3 | 2020 Q4 | 2020 Q3 |
---|
Balance Sheet
Concept | 2021 Q3 | 2020 Q4 | 2020 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $95.03M | $157.3M | $188.3M |
YoY Change | -49.52% | -12.85% | -7.83% |
Cash & Equivalents | $95.74M | $158.0M | $189.0M |
Short-Term Investments | |||
Other Short-Term Assets | $4.554M | $2.607M | $2.469M |
YoY Change | 84.45% | -24.83% | -37.51% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $99.58M | $159.9M | $190.7M |
YoY Change | -47.79% | -13.08% | -8.39% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.833M | $2.286M | $2.397M |
YoY Change | -23.53% | 37.46% | 37.29% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $768.0K | $997.0K | $1.708M |
YoY Change | -55.04% | 5.95% | 104.55% |
Total Long-Term Assets | $6.191M | $8.014M | $8.265M |
YoY Change | -25.09% | 63.58% | 80.03% |
TOTAL ASSETS | |||
Total Short-Term Assets | $99.58M | $159.9M | $190.7M |
Total Long-Term Assets | $6.191M | $8.014M | $8.265M |
Total Assets | $105.8M | $167.9M | $199.0M |
YoY Change | -46.85% | -11.09% | -6.48% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $11.66M | $14.17M | $14.02M |
YoY Change | -16.85% | -9.08% | 8.18% |
Accrued Expenses | $17.89M | $12.25M | $13.99M |
YoY Change | 27.88% | 37.9% | 22.89% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $30.30M | $27.07M | $28.54M |
YoY Change | 6.17% | 9.26% | 15.31% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $4.105M | $4.668M | $4.856M |
YoY Change | -15.47% | 167.05% | 164.06% |
Total Long-Term Liabilities | $4.105M | $4.668M | $4.856M |
YoY Change | -15.47% | 167.05% | 164.06% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $30.30M | $27.07M | $28.54M |
Total Long-Term Liabilities | $4.105M | $4.668M | $4.856M |
Total Liabilities | $34.40M | $31.74M | $33.39M |
YoY Change | 3.03% | 19.66% | 25.6% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$366.4M | ||
YoY Change | 52.63% | ||
Common Stock | $502.6M | ||
YoY Change | 24.9% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $71.37M | $136.1M | $165.6M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $105.8M | $167.9M | $199.0M |
YoY Change | -46.85% | -11.09% | -6.48% |
Cashflow Statement
Concept | 2021 Q3 | 2020 Q4 | 2020 Q3 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P2Y6M | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y2M12D | ||
CY2020Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
805000 | |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
743000 | |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13997000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
71371000 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
162300000 | |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
521000 | |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2586000 | |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-30163000 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
135244000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
1133000 | |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2595000 | |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33424000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
105548000 | |
CY2020Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
87384000 | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-416000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
825000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
26000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
416000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-26000 | ||
CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2341000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-30477000 | |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
165601000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-69780000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-94064000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4181000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7522000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
368000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
318000 | ||
odt |
Non Cash Lease Expense
NonCashLeaseExpense
|
427000 | ||
odt |
Non Cash Lease Expense
NonCashLeaseExpense
|
282000 | ||
us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-111000 | ||
us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-83000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1004000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-904000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2507000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1559000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
5645000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
5110000 | ||
odt |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-477000 | ||
odt |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-225000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-63036000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-81629000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
2459000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
825000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
89843000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-62237000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
7798000 | ||
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
157979000 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
181174000 | |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
95742000 | |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
2861000 | ||
odt |
Non Cash Leasehold Improvements Acquired Through Tenant Improvement Allowance
NonCashLeaseholdImprovementsAcquiredThroughTenantImprovementAllowance
|
719000 | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.08%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Odonate Therapeutics, Inc. (“Odonate” or the “Company”) is a pharmaceutical company formerly focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. In March 2021, the Company announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. The Company has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.08%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, the Company had $95.0 million in cash. The Company has incurred operating losses and negative cash flows from operations since inception. Management believes that the Company’s existing cash will be sufficient to meet the Company’s anticipated cash requirements through at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”).</p> | ||
CY2021Q3 | us-gaap |
Cash
Cash
|
95000000.0 | |
odt |
Cash Requirements Minimum Period
CashRequirementsMinimumPeriod
|
P1Y | ||
CY2021Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3174000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3390000 | |
CY2021Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1341000 | |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1104000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1833000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2286000 | |
CY2021Q3 | us-gaap |
Depreciation
Depreciation
|
100000 | |
us-gaap |
Depreciation
Depreciation
|
400000 | ||
CY2020Q3 | us-gaap |
Depreciation
Depreciation
|
100000 | |
us-gaap |
Depreciation
Depreciation
|
300000 | ||
CY2021Q3 | us-gaap |
Settlement Liabilities Current
SettlementLiabilitiesCurrent
|
12750000 | |
CY2021Q3 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
3383000 | |
CY2021Q3 | odt |
Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
|
688000 | |
CY2020Q4 | odt |
Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
|
9537000 | |
CY2021Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
629000 | |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2658000 | |
CY2021Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
442000 | |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
52000 | |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17892000 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12247000 | |
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y7M6D | |
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.040 | |
CY2021Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
500000 | ||
CY2020Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
600000 | ||
CY2021Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
200000 | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
600000 | ||
CY2020Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
100000 | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
300000 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.47 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
4453283 | ||
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
229000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
935000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
980000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1010000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
953000 | |
CY2021Q3 | odt |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
1299000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
5406000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
557000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4849000 | |
CY2020Q3 | odt |
Litigation Settlement Agreement Amount
LitigationSettlementAgreementAmount
|
12750000 | |
CY2020Q3 | us-gaap |
Litigation Settlement Expense
LitigationSettlementExpense
|
10000000.0 | |
CY2020Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
5614036 | |
CY2020Q3 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
14.25 | |
us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
842105 | ||
CY2020Q3 | odt |
Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
|
92000000.0 | |
CY2020Q3 | us-gaap |
Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
|
87400000 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7229526 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
18.16 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
44429 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
20.45 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
706757 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
21.57 | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2113915 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
16.60 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
200000 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1133549 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
12.42 | |
CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
200000 | |
CY2021Q3 | us-gaap |
Share Price
SharePrice
|
2.91 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2500000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
4600000 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
2900000 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
9500000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
11.26 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
24.02 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P10Y | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P10Y | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
743000 | |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2341000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4181000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7522000 | ||
CY2021Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
15600000 | |
CY2021Q3 | odt |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Including Performance Condition
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostIncludingPerformanceCondition
|
14100000 | |
CY2021Q3 | odt |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Including Performance Condition
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotIncludingPerformanceCondition
|
1500000 | |
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P0Y7M6D | ||
CY2021Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
CY2021Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2021Q1 | us-gaap |
Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
|
11600000 | |
CY2021Q3 | us-gaap |
Restructuring Costs
RestructuringCosts
|
-10000 | |
us-gaap |
Restructuring Costs
RestructuringCosts
|
11600000 | ||
CY2021Q3 | us-gaap |
Restructuring Costs
RestructuringCosts
|
-10000 | |
us-gaap |
Restructuring Costs
RestructuringCosts
|
11645000 | ||
us-gaap |
Restructuring Costs
RestructuringCosts
|
11645000 | ||
us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
8262000 | ||
CY2021Q3 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
3383000 |